A Phase 2 interventional study of Kamada-AAT for Inhalation, 80mg and Placebo in Alpha-1 Antitrypsin Deficiency, sponsored by Kamada, Ltd.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-01-18.
Sponsored by Kamada, Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.
Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one is the 25th largest by enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2014, is one of 20 in phase 2, and was the 37th registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in United States, Denmark, Germany and 6 more countries
Ages 18–80
Tessera Therapeutics, Inc. · Sites in United States, Australia, Netherlands and 2 more countries
Ages 18–70
University of Alabama at Birmingham · Sites in United States
Ages 19+
Columbia University · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 28 · Phase 3 11 · Phase 4 4
First in 1995; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is close to the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 30 across the 55 interventional studies, 190 across the 26 observational. Of the 57 that completed or were terminated, 29 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 81 have an industry lead sponsor. The 10 most frequent:
Kamada, Ltd. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Kamada, Ltd. has 4 studies filed under alpha 1-Antitrypsin Deficiency — fewer than ten, so there is no comparison to draw.
3 of the studies in alpha 1-Antitrypsin Deficiency with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT05297812Columbia UniversityAlpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease | 2027-01 |
| NCT07135427University of Alabama at BirminghamGenetic Variation in IgG in Alpha 1 Antitrypsin Deficiency | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate different doses of "Kamada-AAT for Inhalation" on the levels of alpha 1-proteinase inhibitor and other analytes in epithelial lining fluid (ELF) and serum and to assess the safety of the treatment in subjects with AAT Deficiency.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily inhalation of Kamada-AAT for Inhalation, 80mg
Drug: Kamada-AAT for Inhalation, 80mg
Placebo administered by inhalation daily
Drug: Placebo
Daily inhalation of Kamada-AAT for Inhalation, 160mg
Drug: Kamada-AAT for Inhalation, 160mg
Change From Baseline in the Concentration of Antigenic Alpha-1 Antitrypsin (AAT) in the Lung Epithelial Lining Fluid (ELF)
Patients underwent bronchoalveolar lavage (BAL) prior to initiation of drug and then again after 3 months. Concentration of AAT in the BAL was measured by an enzyme linked immunosorbent assay (ELISA) specific for the normal form of AAT (piM). Urea was also measured in order to determine the dilution factor of the BAL fluid and calculate the concentration of AAT in the ELF.
Time frame: 12 weeks from initiation of study drug
Change From Baseline to 12 Weeks in the Concentration of Functional AAT (Alpha-1 Antitrypsin) in ELF
ITT population with baseline and 12 week values. Patients underwent bronchoalveolar lavage (BAL) prior to initiation of drug and then again after 3 months. Concentration of AAT in the BAL was measured by an antineutrophil elastase capacity (ANEC) assay. Urea was also measured in order to determine the dilution factor of the BAL fluid and calculate the concentration of AAT in the ELF.
Time frame: 12 weeks from initiation of study drug
Change From Baseline in Levels of M Specific AAT in Plasma (PiM)
Intention to treat (ITT) population with baseline and 12 week values.The median change from baseline to Week 12 in the levels of M-specific AAT (piM) in plasma was measured using a specific ELISA assay for M-specific AAT (piM)
Time frame: 12 weeks from initiation of study drug
Change From Baseline in AAT-neutrophil Elastase (NE) Complexes in ELF
Patients underwent a BAL procedure at baseline and 12 weeks and the fluid was analyzed to calculate the change from baseline in the concentration of complexes between AAT and neutrophil elastase in the ELF
Time frame: 12 weeks from initiation of study drug
There were 2 clinical sites. At each site, 18 subjects were recruited and randomized 2:1 to receive either "Kamada-AAT for Inhalation" 80 mg/day (site 1) or 160 mg/day (site 2) or placebo. This gave a total of 12 patients randomized to receive 80 mg/day active drug, 12 patients randomized to receive 160 mg/day active drug, and 12 patients placebo
| Milestone | Kamada-AAT for Inhalation, 80mg | Kamada-AAT for Inhalation, 160mg | Placebo |
|---|---|---|---|
| Started | 12 | 12 | 12 |
| Completed | 12 | 11 | 11 |
| Not completed | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
Patients underwent bronchoalveolar lavage (BAL) prior to initiation of drug and then again after 3 months. Concentration of AAT in the BAL was measured by an enzyme linked immunosorbent assay (ELISA) specific for the normal form of AAT (piM). Urea was also measured in order to determine the dilution factor of the BAL fluid and calculate the concentration of AAT in the ELF.
| nmol | Kamada-AAT for Inhalation, 80mg | Kamada-AAT for Inhalation, 160mg | Placebo |
|---|---|---|---|
| Change From Baseline in the Concentration of Antigenic Alpha-1 Antitrypsin (AAT) in the Lung Epithelial Lining Fluid (ELF) | 4551.023 (2587 to 6835.6) | 13454.772 (1020.7 to 70907.95) | -27.15 (-103.6 to 196.7) |
ITT population with baseline and 12 week values. Patients underwent bronchoalveolar lavage (BAL) prior to initiation of drug and then again after 3 months. Concentration of AAT in the BAL was measured by an antineutrophil elastase capacity (ANEC) assay. Urea was also measured in order to determine the dilution factor of the BAL fluid and calculate the concentration of AAT in the ELF.
| nmol | Kamada-AAT for Inhalation, 80mg | Kamada-AAT for Inhalation, 160mg | Placebo |
|---|---|---|---|
| Change From Baseline to 12 Weeks in the Concentration of Functional AAT (Alpha-1 Antitrypsin) in ELF | 2766.343 (840.9 to 3800.3) | 3557.563 (1582.8 to 10673.2) | 5.831 (-1032 to 884.3) |
Intention to treat (ITT) population with baseline and 12 week values.The median change from baseline to Week 12 in the levels of M-specific AAT (piM) in plasma was measured using a specific ELISA assay for M-specific AAT (piM)
| nM | Kamada-AAT for Inhalation, 80mg | Kamada-AAT for Inhalation, 160mg | Placebo |
|---|---|---|---|
| Change From Baseline in Levels of M Specific AAT in Plasma (PiM) | 113.17 (56.3 to 158.1) | 90.73 (37.3 to 369.7) | -4.02 (-9.8 to 4.9) |
Patients underwent a BAL procedure at baseline and 12 weeks and the fluid was analyzed to calculate the change from baseline in the concentration of complexes between AAT and neutrophil elastase in the ELF
| nM | Kamada-AAT for Inhalation, 80mg | Kamada-AAT for Inhalation, 160mg | Placebo |
|---|---|---|---|
| Change From Baseline in AAT-neutrophil Elastase (NE) Complexes in ELF | 38.71 (8.4 to 66.8) | 46.225 (17.6 to 436.3) | 0 (-2 to 1.3) |
Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Kamada-AAT for Inhalation, 80mg | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Kamada-AAT for Inhalation, 160mg | 0/12 (0%) | 1/12 (8.3%) | 8/12 (66.7%) |
| Placebo | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Event | Kamada-AAT for Inhalation, 80mg | Kamada-AAT for Inhalation, 160mg | Placebo |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/12 | 1/12 | 0/12 |
| Event | Kamada-AAT for Inhalation, 80mg | Kamada-AAT for Inhalation, 160mg | Placebo |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 4/12 | 1/12 | 3/12 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/12 | 2/12 | 0/12 |
| PyrexiaGeneral disorders | 2/12 | 0/12 | 0/12 |
| NasopharyngitisInfections and infestations | 2/12 | 2/12 | 2/12 |
| Upper respiratory tract infectionInfections and infestations | 2/12 | 1/12 | 1/12 |
| HeadacheNervous system disorders | 2/12 | 0/12 | 1/12 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 0/12 | 2/12 | 0/12 |
| Pulmonary congestionRespiratory, thoracic and mediastinal disorders | 0/12 | 0/12 | 2/12 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 1/12 | 2/12 | 0/12 |
| Lip swellingGastrointestinal disorders | 0/12 | 0/12 | 1/12 |
ITT population
| Age, Continuous(years) | Kamada-AAT for Inhalation, 80mg | Kamada-AAT for Inhalation, 160mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 55.5 ± 8.69 | 55.3 ± 10.13 | 56.3 ± 4.77 | 55.7 ± 7.96 |
| Sex: Female, Male(Participants) | Kamada-AAT for Inhalation, 80mg | Kamada-AAT for Inhalation, 160mg | Placebo | Total |
|---|---|---|---|---|
| Female | 9 | 7 | 8 | 24 |
| Male | 3 | 5 | 4 | 12 |
| Race/Ethnicity, Customized(Participants) | Kamada-AAT for Inhalation, 80mg | Kamada-AAT for Inhalation, 160mg | Placebo | Total |
|---|---|---|---|---|
| White Non-Hispanic | 12 | 12 | 12 | 36 |
| Region of Enrollment(participants) | Kamada-AAT for Inhalation, 80mg | Kamada-AAT for Inhalation, 160mg | Placebo | Total |
|---|---|---|---|---|
| United States | 12 | 12 | 12 | 12 |
| BMI(kg/m^2) | Kamada-AAT for Inhalation, 80mg | Kamada-AAT for Inhalation, 160mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 30.0 ± 4.3 | 28.3 ± 8.3 | 25.8 ± 4.5 | 28.0 ± 6.1 |
| %Predicted forced expiratory volume in one second (FEV1)(%) | Kamada-AAT for Inhalation, 80mg | Kamada-AAT for Inhalation, 160mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 81.7 ± 17.9 | 73.2 ± 20.1 | 78.1 ± 20.0 | 77.6 ± 19.1 |
The record gives a start of Apr 2014, a primary completion of Feb 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2020, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
alpha 1-Antitrypsin Deficiency →
Kamada, Ltd.